Xenon Pharmaceuticals/$XENE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Ticker
$XENE
Sector
Primary listing
Employees
322
Headquarters
Burnaby, Canada
Website
XENE Metrics
BasicAdvanced
$3B
-
-$3.54
1.17
-
Price and volume
Market cap
$3B
Beta
1.17
52-week high
$44.56
52-week low
$26.74
Average daily volume
914K
Financial strength
Current ratio
15.138
Quick ratio
14.786
Long term debt to equity
1.145
Total debt to equity
1.375
Profitability
EBITDA (TTM)
-315.496
Gross margin (TTM)
-3,268.36%
Net profit margin (TTM)
-3,709.71%
Operating margin (TTM)
-4,241.60%
Effective tax rate (TTM)
1.55%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-25.52%
Return on equity (TTM)
-37.65%
Valuation
Price to revenue (TTM)
406.363
Price to book
4.71
Price to tangible book (TTM)
4.71
Price to free cash flow (TTM)
-13.165
Free cash flow yield (TTM)
-7.60%
Free cash flow per share (TTM)
-2.95
Growth
Earnings per share change (TTM)
29.66%
3-year revenue growth (CAGR)
-29.23%
10-year revenue growth (CAGR)
-11.73%
3-year earnings per share growth (CAGR)
34.12%
10-year earnings per share growth (CAGR)
22.04%
What the Analysts think about XENE
Analyst ratings (Buy, Hold, Sell) for Xenon Pharmaceuticals stock.
Bulls say / Bears say
Xenon was included in the Russell 3000® and Russell 2000® Indexes on June 27, 2025, boosting its profile with institutional investors and likely supporting increased passive investment (TradingView/Reuters)
As of June 30, 2025, Xenon reported $624.8 million in cash, cash equivalents, and marketable securities, extending its financial runway into 2027 to fund ongoing late-stage programs (GlobeNewswire)
Patient enrollment for the Phase 3 X-TOLE2 focal onset seizure trial was completed in Q2 2025, setting the company up to deliver topline data in early 2026—a major milestone toward Xenon’s first potential commercial launch (GlobeNewswire)
Xenon’s net loss expanded to $84.7 million in Q2 2025 from $57.9 million a year ago, mainly due to higher R&D spending related to its azetukalner programs (GlobeNewswire)
In Q2 2025, Xenon generated no product revenues and remains reliant on collaboration payments, highlighting its continued absence of a commercial product (Nasdaq)
The investigator-sponsored Phase 2 MDD study failed to achieve its primary neuroimaging endpoint, raising concerns about azetukalner’s effectiveness in neuropsychiatric disorders (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2025.
XENE Financial Performance
Revenues and expenses
XENE Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals (XENE) has a market cap of $3B as of September 05, 2025.
What is the P/E ratio for Xenon Pharmaceuticals stock?
The price to earnings (P/E) ratio for Xenon Pharmaceuticals (XENE) stock is 0 as of September 05, 2025.
Does Xenon Pharmaceuticals stock pay dividends?
No, Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next Xenon Pharmaceuticals dividend payment date?
Xenon Pharmaceuticals (XENE) stock does not pay dividends to its shareholders.
What is the beta indicator for Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.